COVID-19 Inquiry Receives More Than 31,000 Submissions
'My fellow Commissioners and I sincerely thank everyone who shared their COVID-19 experience with the Inquiry. We are grateful to those who took the time to make a submission, especially on topics that still bring difficult memories for many people,' says Grant Illingworth KC, Chair of the COVID-19 Inquiry.
Phase Two of the COVID-19 Inquiry began on 29 November 2025. The public submissions portal closed on Sunday 27 April 2025.
The COVID-19 Inquiry received submissions from every region in Aotearoa New Zealand, from Te Tai Tokerau Northland to Murihiku Southland. The region with the highest number of submissions was Tāmaki Makaurau Auckland, with just under 7,500 submissions. The Inquiry also saw large numbers of submissions coming from Te Tai Tokerau Northland and Whakatū Nelson.
'It's clear that the pandemic is still top of mind for many people in Aotearoa New Zealand, particularly those areas like Auckland and Northland that were affected by longer lockdowns during the COVID-19 response,' says Mr Illingworth.
The Inquiry also heard from a range of ethnic groups and communities (NZ European, Māori, Pasifika, Asian communities, and those from the Middle East and Latin America), as well as a range of age groups (from under 18 to over 85). Nearly 25% of submissions came from those aged 55-64. The Inquiry heard from a wide range of people, with the majority of submissions coming from women (almost 60%).
Phase Two of the COVID-19 Inquiry is tasked with looking at the key decisions made by the New Zealand Government during 2021 and 2022 on vaccine mandates, safety, and approvals, the use of lockdowns, and testing, tracing, and non-pharmaceutical public health materials (like masks). Some of these topics, like vaccine safety, were not included in Phase One of the Inquiry, while others build on the work of Phase One – like lockdowns and mandates. The overall purpose of the COVID-19 Inquiry is to review Aotearoa New Zealand's response to the COVID-19 pandemic to help prepare for future pandemics.
'We have heard from New Zealanders on all topics that are a focus for Phase Two,' says Mr Illingworth. 'We are seeing that vaccine mandates and vaccine safety are a priority for most submitters, followed by the use of lockdowns.'
The sentiment of submissions ranges widely, from those who are critical of the New Zealand Government's response as a whole, to those who are positive about the overall response, as well as many who hold mixed views about the response.
As well as considering the submissions received during Phase Two, the Inquiry will also be considering any non-confidential submissions from Phase One that cover topics being assessed in Phase Two, as well as information provided during the consultation on the Inquiry's terms of reference in early 2024.
'The COVID-19 Inquiry is focused on addressing the questions the public wants answered about the pandemic, and making sure the concerns and experiences of everyone who experienced Aotearoa's pandemic response are heard,' says Mr Illingworth.
The Inquiry will continue seeking evidence through meetings with key decision-makers and advisers, engagements with impacted communities, and public hearings to be held later in 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
2 days ago
- RNZ News
Antibiotic use likely fuelled the rise of a 'superbug' in NZ - genomics offers a defence against the next threat
By Rhys Thomas White, Juliet Elvy, Kristin Dyet, Maria Hepi, Nigel French and Sarah Bakker* of After a routine C-section at an Auckland hospital, a mother developed severe pain and what seemed like postnatal fatigue. It turned out to be an infection with methicillin-resistant Staphylococcus aureus (MRSA), a "superbug" spreading across New Zealand and beyond. Her story isn't unique. In Dunedin, another mother was diagnosed with MRSA and internal bleeding postpartum. These are personal stories, but they are also early warning signals of a broader health security challenge. Methicillin is an antibiotic from the penicillin family, and MRSA is resistant to it (and often to other types of antibiotics). This makes infections harder to treat. Once considered mainly a hospital problem, methicillin-resistant infections are now common in the community. An MRSA strain that emerged in New Zealand (named AK3) is now the dominant strain in our communities. The country's antibiotic-dispensing habits may have helped it emerge and spread. AK3 was first detected in 2005. Today, it is the leading cause of MRSA infections in New Zealand and, as our new study shows, has also been detected in the South Pacific and Europe. Using whole-genome sequencing, we traced the journey of AK3 from a drug-susceptible ancestor to a highly resistant clone. Along the way, AK3 acquired key resistance genes, including those conferring resistance to methicillin and fusidic acid, a topical antibiotic once prescribed at historically high rates in New Zealand . Dispensing of topical fusidic acid has declined since 2016. But once resistance becomes common, it can be difficult to reduce or revert to a susceptible form. This is why it is so important to preserve the effectiveness of antibiotics by using them carefully and only when needed (a practice known as antimicrobial stewardship), and to monitor resistance trends using genomic surveillance. In New Zealand, fusidic acid was once widely prescribed in the community to treat skin infections , often without a confirmed diagnosis. This widespread use created ideal conditions for fusidic acid resistance to develop. The emergence of AK3 demonstrates how antibiotics, when overused at a national scale, can drive the evolution of globally significant resistance. Our genomic study has improved our understanding of how AK3 evolved and became dominant in New Zealand. Our analyses and public health data show that AK3 does not affect all groups equally. Compared with people of European ethnicity, Māori are three times more likely, and Pacific peoples nearly five times more likely, to suffer from skin infections caused by S. aureus. Socio-economic factors amplify the risk: those in the most deprived areas are nearly four times more likely to be hospitalised with skin infections. The burden of skin infections and overuse of fusidic acid created the conditions for AK3 to emerge, adapt and spread. For people with AK3 and other resistant superbugs, it is critical to preserve the effectiveness of antibiotics. Fusidic acid still has a role in treatment, but the goal is to strike the right balance between under- and over-prescribing. Addressing this requires improved access to timely, appropriate care and treatment in the communities most affected. This is a reminder that even the most advanced technologies cannot, on their own, overcome structural barriers. If we are serious about the threat antimicrobial resistance poses, we must confront these inequities head-on. Recently, we detected AK3 in a sample of raw milk collected directly from a cow with mastitis during veterinary testing - well before any processing, and not from milk intended for people to drink. Resistance genes can cross human, animal and environmental boundaries and this demands a "One Health" approach, integrating surveillance with coordinated policy and action across all domains. Surveillance is the continuous and systematic collection of data to inform public health action, typically drawing from multiple sources, including laboratory results, epidemiological information and genomic analysis. The rise of AK3 underscores the need for a proactive, integrated antimicrobial resistance strategy across science, policy, veterinary and public health. Genomics is a key strategic priority, supporting an evidence-based approach to current and emerging diseases. The case of AK3 brings these priorities into sharp focus and shows why coordinated action is essential to stay ahead of emerging threats. To protect New Zealand's health security and economy, we must support appropriate antimicrobial use. The right antibiotic should be used at the right time and in the right dose, guided by local data on microbial resistance and supported by accessible diagnostics. We must also expand antimicrobial resistance surveillance and strengthen monitoring across human, animal and environmental health, with genomic analysis as a core component so that threats can be detected and transmission disrupted earlier . The stories of two mothers whose MRSA infections complicated childbirth are more than case studies. They are calls to action and AK3 is our test. It challenges us to move from reactive treatment to proactive prevention. New Zealand has the tools, talent, technology and networks to lead in antimicrobial surveillance and response. But we must act decisively. Not just to contain AK3, but to prevent the next superbug from emerging. Let's treat antibiotics like the critical infrastructure they are, recognising that the pipeline for new antibiotics is very narrow. We must make sure antibiotics will still work when we need them most. Publicly funded dispensing of topical fusidic acid in New Zealand, 2001 to 2023. Key events include the first detection of MRSA AK3 in 2005, AK3 becoming dominant in 2009, a peak in dispensing in 2013, and a marked decline following 2016. The yellow band marks the critical period of AK3 expansion, while the grey band represents the COVID-19 border control period. Photo: Pharmaceutical Collection, Te Whatu Ora; Stats NZ; figure created by PHF Science * Rhys Thomas White - Scientist in Genomics and Bioinformatics, New Zealand Institute for Public Health and Forensic Science; Juliet Elvy - Clinical Microbiologist, New Zealand Institute for Public Health and Forensic Science; Kristin Dyet - Senior Scientist in Microbiology, New Zealand Institute for Public Health and Forensic Science; Maria Hepi - Senior Social Scientist, New Zealand Institute for Public Health and Forensic Science; Nigel French - Distinguished Professor of Infectious Disease Epidemiology and Public Health, Te Kunenga ki Pūrehuroa - Massey University; Sarah Bakker - Scientist in Health Security, New Zealand Institute for Public Health and Forensic Science. - This story originally appeared on The Conversation.
NZ Herald
2 days ago
- NZ Herald
Small Business: Dopaw brings glamour to raw pet food for paws-itive health
I did my master's in science, specifically in animal metabolism and nutrition. During my degree, I created diets and looked at the differences in proteins and metabolism, and I really loved that part of it. Over a few wines with my mum, we talked and realised there was a gap when it comes to raw pet food, which we've always used. As a customer, if you go to the supermarket or if you're online, nothing ever stands out or looks the part when it comes to raw food. I wanted to really change the way people see raw pet food, and if they can see it on a supermarket shelf and actually be drawn to it, then they'll take a deeper look and see how good it can be. Raw food diets are good for dogs joints, their digestion, their skin health, their coats and can help with allergies. What is the raw meat diet, and is it safe for pets? There are heaps of benefits to raw food for dogs. It helps their joints, their digestion, their skin health, dealing with allergies, it can make their coats shinier, and it can help with smelly stools as well. So it's good in all different ways. If you're going to compare it straight to a processed diet, such as kibble, the way kibble is formulated is they cook out all of the proteins. It gets de-natured through that process, and so you don't get as much of that good stuff as you would if it's completely raw. The less something is processed, the better it is. If you're going to switch your dog from a processed diet to a raw food diet, you want to transition them slowly. That's to do with digestion. If we were to change our diet straight away, we're going to get an upset stomach, and it's the same for pets. Is the business self-funded, and have your costs gone up? Yes it is, we don't have any outside investors, so that makes it a lot easier to run things. But at the same time, we've got to be smart with what we're doing. It's become more expensive to make pet food, and that all comes from the supplier side. They set the price to get product in bulk, especially if you're after a certain quality of ingredient. We're in the process of expanding, so very soon we're going to be able to buy bigger quantities, which means a smaller price. But a lot of small businesses can only buy that product in smaller quantities, which means the price is going to be a lot higher. Small and large businesses just have no choice but to increase prices for consumers. The demand for pet food has also increased since Covid. Everyone got pets, they were around pets more, and they wanted to buy different things for their animals. Dopaw is a raw pet-food business, specialising in treats, aiming to bring "a bit of glamour and sparkle" to the pet-food market. What has been the biggest challenge in starting the business? I would say there's a few that I didn't realise when going into it. One is transport, especially for a raw pet food, because it has to be refrigerated. We're lucky in New Zealand that we have NZ Post, which helps with that, but it can be so challenging at a time like Black Friday or Christmas. We've had to close the shop early because, if it doesn't get there overnight, it's not going to be great. There's also competition for retail space as a frozen goods company. The big companies like Animates and Petstock have limited freezer space, so competing for that is really difficult. If you're dry food, there's a lot more shelf space for you. What would be your advice to a budding entrepreneur wanting to start a business? I would say don't be afraid. You might be scared of what challenges are to come but, no matter what, you're going to learn along the way. Even the best business owners in the world, if they're going to start a business, they're going to have a challenge they'll learn to overcome. Don't be afraid to just back yourself and do it. Do you have a small business story you want to share? Send your pitches to Tom Raynel is a multimedia business journalist for the Herald, covering small business, retail and tourism.
NZ Herald
3 days ago
- NZ Herald
The shocking roadblocks to timely cardiac care in New Zealand
Listening to articles is free for open-access content—explore other articles or learn more about text-to-speech. Study puts the total cost of heart disease deaths in 2020 at $13.09 billion. Image / Getty Images The Kia Manawanui Trust has shone a shocking spotlight on the roadblocks to timely cardiac care in New Zealand, but members are optimistic things can be fixed. Cardiac care in New Zealand is in trouble. There are extensive delays for surgery, a shortage of specialists, long waits for scans, and lack of access to drugs that would help heart patients. Two years ago, officials considered sending patients to Australia for treatment because the situation here was so dire, and not for the first time. The Kia Manawanui Trust (it means 'the heart of Aotearoa') is out to try to make a difference. A sister charity to the Asthma and Respiratory Foundation, it set out in 2018 to identify the problems and find ways to fix them. 'This is a major killer in New Zealand,' says CEO Letitia Harding. 'We're going to find out where the bottlenecks are, what lobbying needs to be done, why we don't have devices and medical interventions you can get overseas that we know save lives, and we're going to start raising awareness and pushing for change.' One of the trust's first successes was to raise funds for portable electrocardiogram (ECG) machines to be sent to under-served communities. It has also run a certified course in intravascular imaging, a technique that can significantly reduce cardiac death as it allows doctors to see inside blood vessels to assess the severity of disease. Now, it has funded research by Otago University which has pinpointed just how badly heart care in New Zealand is lagging. Almost half of all heart attack patients are not being treated within internationally accepted timeframes, the 'Heart Disease in Aotearoa' report found. Areas with the fewest cardiac specialists – Tairāwhiti, Whanganui and the central North Island – have the highest death rates. Māori and Pasifika are hospitalised or die from heart disease on average a decade earlier than the population as a whole. Auckland is the only region where the number of specialists per head of population is comparable to European countries. The study put the total cost of heart disease deaths in 2020 at $13.09 billion. 'The lack of investment in the cardiac space has been going on for many, many years,' says Harding. 'I don't blame one government or the other, this has been decades. 'We're going to make some noise and come up with solutions.' Harding says it isn't such a stretch for a charity focused on respiratory health to become involved with cardiac care, too. 'The heart and lungs are related,' she points out. 'We know that COPD [chronic obstructive pulmonary disease] can lead to heart failure, for instance. And when the Asthma and Respiratory Foundation was talking about vaping issues, more and more literature was coming out on how it affects not just the lungs but the heart.' In a bid to tackle the shortage of cardiac sonographers, Te Whatu Ora Health New Zealand has already partnered with the University of Auckland to launch a training programme for at least 15 students per year. However, during their studies they need to train in a cardiology department, and Harding says there's no budget for that. Ringfencing funding is among a list of solutions the trust has suggested to Health Minister Simeon Brown. Kia Manawanui also wants to see more funding for dedicated cardiac beds at hospitals in main centres, an end to delays in hiring new medical staff when someone leaves a hospital position, and a commitment to tackling the waitlist for ECGs. The trust estimates at least 15,000 patients are waiting for heart scans to diagnose potentially life-threatening conditions and has called for locum staff to be used to run extra clinics to clear the backlog. Particularly in rural areas, there are delays for patients who need heart scans that could detect atrial fibrillation early. The condition can lead to heart failure and affects about one in 35 Kiwis. Te Whatu Ora has announced plans to shorten hospital waiting lists by outsourcing simpler 'elective' procedures to private surgeons. Harding agrees this could ease the pressure on the health system. 'But private hospitals don't do acute services. They aren't going to be seeing the heart attack patients at 3am – they go to the public hospital. 'There is a place for the public-private partnership model this government is obviously very keen on. But you still have to invest in secondary hospitals that are screaming out for more beds.' Harding is optimistic that the trust can make a difference. 'There was a need for someone to speak out about the issues going on in the cardiac space. Heart disease affects so many lives and we're really excited to get into this new area.'
